Fennec (FENC) Pharmaceuticals has repurchased and redeemed all of Fennec’s outstanding convertible notes issued to Petrichor Opportunities Fund I LP and Petrichor Opportunities Fund I Intermediate LP using proceeds from the closing of the Company’s previously announced underwritten public offering in the United States and concurrent private placement in Canada, closed on November 17 and 18, 2025, respectively. The Company has no outstanding debt after the redemption of Petrichor’s convertible notes. The aggregate repurchase and redemption price of the Petrichor notes was $21,729,455.30. Before the repurchase and redemption, the Petrichor notes bore interest at a rate equal to the prime rate, as published in The Wall Street Journal, with a floor of 3.5%, plus an applicable margin rate of 4.5% and, prior to our agreement with Petrichor to repurchase and redeem the Petrichor Notes, were set to mature on August 19, 2027.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FENC:
- Fennec Pharmaceuticals Closes $5M Private Offering in Canada
- Fennec Pharmaceuticals Reports Increased PEDMARK Sales
- Fennec Pharmaceuticals Announces Underwriting Agreement for Share Offering
- Fennec 4.7M share Spot Secondary priced at $7.50
- Fennec Pharmaceuticals Prices Public Offering to Raise $35 Million